Agilent and ExonHit Enters into Marketing Alliance
News Jun 01, 2006
Agilent Technologies Inc. and ExonHit Therapeutics have announced that they have entered into a marketing alliance in which Agilent will market and sell nine different ExonHit human and mouse SpliceArrays as commercial products.
These SpliceArrays include GPCR, Ion Channel, nuclear receptors and apoptosis pathways.
"Splice variant analysis is the next natural development in gene-expression technology, and we see it as holding important value for the biomedical research community," said Fran DiNuzzo, Agilent vice president and general manager, Integrated Biology Solutions.
"SpliceArray technology also complements our portfolio of microarray-based research tools, and the ExonHit team has proven to be a source of well-designed solutions."
"We are excited to take this step, which broadens the relationship between our companies," said Bruno Tocque, president of ExonHit's Management Board.
"Agilent is a technology and market leader in the field of microarrays, and we are very pleased to be partners with them in the broader commercialization of this new generation of microarrays."
ExonHit SpliceArrays originally became available through Agilent in August 2005, and based on the success of that collaboration, the two companies expanded the agreement.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.